New 6-Month drug cocktail aims to tame resistant TB
NCT ID NCT07675954
First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time
Summary
This phase 3 trial tests whether a 6-month combination of five drugs (bedaquiline, delamanid, delpazolid, levofloxacin, and pyrazinamide) works as well as standard treatment for rifampicin-resistant tuberculosis in adults and adolescents aged 15 and older in South Africa. The study also checks if this new regimen causes fewer side effects. Participants are randomly assigned to either the experimental or standard treatment and followed for 12 months after therapy ends.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
MDR-END Plus regimen (bedaquiline, delamanid, delpazolid, levofloxacin, pyrazinamide)
What this could lead to
If successful, this could provide a shorter, safer, and more tolerable treatment option for drug-resistant tuberculosis, potentially improving cure rates.
What could go wrong
This is a phase 3 trial, but results may not confirm non-inferiority or safety advantages. The regimen may still cause side effects or require treatment extensions.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RIFAMPICIN-RESISTANT TUBERCULOSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Desmond Tutu TB Centre, Brooklyn Chest Hospital Trial Unit
Cape Town, Western Cape, 7405, South Africa
Contact
Contact Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Perinatal HIV Research Unit, PHRU-Matlosana, Tshepong Hospital
Klerksdorp, North West, 2571, South Africa
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Email: •••••@•••••
Contact